Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

Rhea-AI Summary

Lisata Therapeutics, Inc. (Nasdaq: LSTA) has completed enrollment in the Phase 2b ASCEND study of its novel agent, LSTA1, for the treatment of metastatic pancreatic ductal adenocarcinoma. Top-line data is expected in the fourth quarter of 2024, with complete data by mid-2025. The trial evaluates the efficacy of LSTA1 in combination with standard-of-care gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.

Enrollment completed approximately six months earlier than originally projected

Top-line placebo-controlled, blinded, randomized data now expected in the fourth quarter of 2024

BASKING RIDGE, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that a critical milestone has been achieved with the completion of enrollment in the Phase 2b ASCEND study of its novel agent, LSTA1, for the treatment of metastatic pancreatic ductal adenocarcinoma (“mPDAC”). Lisata expects top-line data from the 95 patients assigned to Cohort A of the study to be reported in the fourth quarter of 2024 and the complete data set of all 155 patients from the study by mid-2025.

The ASCEND trial is a 155-patient, double-blind, randomized, placebo-controlled Phase 2b clinical trial evaluating standard-of-care (“SoC”) gemcitabine and nab-paclitaxel vs SoC plus LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma. LSTA1 is Lisata’s lead development candidate designed to augment the targeting to and penetration of anti-cancer drugs in solid tumors expressing a dense stromal barrier without exacerbating any adverse effects normally associated with those anti-cancer drugs. Study participants are randomized 2:1 in favor of study intervention (SoC + LSTA1) vs. SoC plus placebo. Cohort A, where patients received a single dose of LSTA1 plus SoC, has 80% power with 95% confidence to detect a 16% increase in the 6-month progression-free survival (“PFS”) rate in the experimental arm vs. the control arm (SoC + placebo). Cohort A dosing is identical to the dosing used in the previously reported Phase 1b/2a trial in which substantial improvement was shown in both PFS and overall survival (“OS”) in mPDAC patients administered LSTA1 plus SoC. Cohort B will assess whether a second dose of LSTA1, administered 4 hours after the original dose of LSTA1 plus SoC, will further improve patient outcomes. Both PFS and OS will be assessed in the trial. The trial is being conducted at up to 30 sites in Australia and New Zealand, led by the Australasian Gastro-Intestinal Trials Group (“AGITG”) in collaboration with the University of Sydney and with the National Health and Medical Research Council Clinical Trial Centre at the University of Sydney (“CTC”) as the Coordinating Centre. The trial is approved by the Sydney Local Health District (“SLHD”) Ethics Review Committee (Royal Prince Alfred Hospital Zone) (2021/ETH00985) and is fully funded by Lisata through an unrestricted research support agreement.

“The completion of enrollment in ASCEND is a vital step in the development of LSTA1; exceeding the original enrollment completion expectations and, as a result, accelerating the expected timeline for seminal data by nearly 12 months,” stated David J. Mazzo, PhD, President and Chief Executive Officer of Lisata. “This speaks to the tremendous effort on the part of AGITG and CTC as well as the unmet need of patients with mPDAC. We believe LSTA1 has the potential to transform the treatment landscape for this and many other devastating solid tumor cancers. We look forward to reporting Cohort A top-line results from this study in the fourth quarter of next year, which, if positive, will be used to explore accelerated approval applications with regulatory bodies around the world. Additionally, the results of ASCEND will be the basis for the design of the most efficient and cost-effective Phase 3 trial if that is the necessary next step in development.”

About LSTA1

LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., covalently bound) anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor. LSTA1 also has the potential to modify the tumor microenvironment, with the objective of making tumors more susceptible to immunotherapies. Lisata and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies and RNA-based therapeutics. Additionally, LSTA1 has demonstrated favorable safety, tolerability, and activity in clinical trials to enhance delivery of SoC chemotherapy for pancreatic cancer. Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively.

About Lisata Therapeutics

Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Based on Lisata’s CendR Platform^® Technology, Lisata has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected that its current business and development plan is funded with available capital through these milestones and into early 2026. For more information on the Company, please visit www.lisata.com.

About the AGITG

The Australasian Gastro-Intestinal Trials Group (AGITG) is a multi-disciplinary collaborative group that undertakes patient-centric research to advance medical care and practice in the treatment of gastro-intestinal cancer. Since 1991, the AGITG has led 74 GI cancer clinical trials, enrolling 8,800 patients across 129 hospitals in Australia and New Zealand, and 125 sites globally. Learn more

About the University of Sydney

As Australia’s first university – founded in 1850 – the University of Sydney has a proud history of global leadership in education and research and inspiring people from all backgrounds to contribute to positive real-world change. The University of Sydney is a world-renowned teaching and research institution – our research combines the expertise and talents of scholars from many disciplines. Learn more 

About the NHMRC Clinical Trials Centre, University of Sydney

The NHMRC Clinical Trials Centre is a flagship research centre of the Faculty of Medicine and Health at the University of Sydney that designs and manages clinical trials. This includes responsibility for study coordination, monitoring, data acquisition and management and statistical analysis. The NHMRC Clinical Trials Centre has health economics, biostatistics, systematic reviews and biomarker teams work with trial data and inform healthcare providers about best practice. Learn more

Forward-Looking Statements

This communication contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, future revenue, projected expenses and capital, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this communication, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Lisata or its management, may identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements relating to Lisata’s continued listing on the Nasdaq Capital Market; expectations regarding the capitalization, resources and ownership structure of Lisata; the approach Lisata is taking to discover and develop novel therapeutics; the adequacy of Lisata’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; and the difficulty in predicting the time and cost of development of Lisata’s product candidates. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the safety and efficacy of Lisata’s product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in Lisata’s clinical programs, Lisata’s ability to finance its operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of Lisata’s scientific studies, Lisata’s ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in Lisata’s markets, the ability of Lisata to protect its intellectual property rights; and legislative, regulatory, political and economic developments. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Lisata’s Annual Report on Form 10-K filed with the SEC on March 30, 2023, and in other documents filed by Lisata with the Securities and Exchange Commission. Except as required by applicable law, Lisata undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Investors and Media:

Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com

FAQ

What is the ticker symbol for Lisata Therapeutics, Inc.?

The ticker symbol for Lisata Therapeutics, Inc. is LSTA (Nasdaq: LSTA).

What is the Phase 2b ASCEND study of LSTA1?

The Phase 2b ASCEND study is evaluating the efficacy of LSTA1, a novel agent, for the treatment of metastatic pancreatic ductal adenocarcinoma.

When is the top-line data expected from the ASCEND study?

The top-line data from the ASCEND study is expected in the fourth quarter of 2024.

What is the goal of the ASCEND trial?

The goal of the ASCEND trial is to assess the potential of LSTA1 in improving patient outcomes in metastatic pancreatic ductal adenocarcinoma.

Who is leading the ASCEND trial?

The ASCEND trial is led by the Australasian Gastro-Intestinal Trials Group (AGITG) in collaboration with the University of Sydney and the National Health and Medical Research Council Clinical Trial Centre at the University of Sydney (CTC).